NICE has today published a new rapid COVID-19 guideline to help healthcare staff identify and treat patients who develop the rare syndrome vaccine-induced immune thrombocytopenia and thrombosis (VITT) after receiving COVID-19 vaccinations.

Clinical trial evidence is uncertain and it is unlikely that collecting more data in the Cancer Drugs Fund would resolve the uncertainties, according to the draft guidance.

Treatment with ravulizumab must be under the advice of the national renal complement therapeutics service.

Ravulizumab is accepted for restricted use.

Treatment accepted for restricted use within NHS Scotland.

Avatrombopag is accepted for use within NHS Scotland for severe thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo an invasive procedure.

Monitor serum phosphate levels in patients treated with multiple high-dose administrations, or those on long-term treatment, and in those with pre-existing risk factors for hypophosphataemia.